ANIP · NASDAQ · STOCK
ANI Pharmaceuticals (ANIP) Stock Analysis
$73.89
52W $69.58 – $97.00
63/100
$1.68B
15.3
0.49
Is ANIP Bullish or Bearish?
Bullish.
Innellis AI committee rates ANI Pharmaceuticals, Inc. (ANIP) Buy with a composite score of 63/100
, based on 5 analysts with 80% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.33 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.67 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 30.9% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 19.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 30.9% YoY -- genuine top-line momentum — Growth
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- News sentiment is positive (+0.17 across 6 articles, 14d) — News
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
- Daily trend (downtrend) conflicts with the weekly trend (uptrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
63/100
Agreement
80%
Analysts
5
Conviction
Contested
Sector Rank
Top 16%
of 192 Healthcare peers
Value Analyst
bullish
63
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ ROE of 19.6% shows genuine earnings power backing the valuation
Growth Analyst
bullish
83
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 30.9% YoY -- genuine top-line momentum
Technical Analyst
bearish
39
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− Price structure making lower highs and lower lows
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
63
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.17 across 6 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 62.7 to 62.7.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
57.4
Neutral
MACD Histogram
-0.018
Bearish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$70.15
Resistance
$86.67
Bollinger %B
0.52
Inside Bands
Price vs Moving Averages
EMA 9
$72.84
Above
EMA 21
$73.31
Above
EMA 50
$74.72
Below
EMA 200
$77.54
Below
Fundamental Analysis
Valuation
94
Growth
94
Profitability
70
Financial Health
99
Cash Flow
70
Valuation
P/E Ratio
15.3×
P/B Ratio
2.62×
PEG Ratio
0.01
Dividend Yield
0.00%
52W High
$97.00
52W Low
$69.58
Quality & Growth
ROE
1448.7%
ROA
543.9%
Gross Margin
6523.0%
Operating Margin
1534.9%
Revenue Growth YoY
—
Debt / Equity
0.55
AI Fundamental Assessment
P/E ratio of 15.3 (inexpensive relative to a 15-40x range); Price-to-book of 2.6x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.5%; Return on assets of 5.4%; Net margin of 10.8%; Gross margin of 65.2%; Current ratio of 2.91 (healthy short-term liquidity); Debt-to-equity of 0.55; Free cash flow per share is positive (7.54); Most recent quarter beat estimates by 5.7%; 4 consecutive earnings beats; EPS growth accelerating (-12.0% -> +7.8% QoQ); Analyst estimates rising over recent quarters
Get the Full ANIP Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →